More on TLX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $10.46 |
|
|||
| Open | $10.46 | ||||
| 52 Wk High | $2.18 | ||||
| 52 Wk Low | $0.30 | ||||
| Day High | $10.46 | ||||
| Day Low | $10.46 | ||||
| P/E | N/A | ||||
| EPS | $-3.32 | ||||
| Volume | 346 | ||||
- RBC Capital Downgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Sector Perform
- First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
- Citi Opens 30-Day upside catalyst watch on Telix Pharmaceuticals Ltd (TLX:AU) (TLX)
- Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Lowered to AUD31 at Citi
- Telix Pharmaceuticals Ltd (TLX) PT Lowered to $22 at Citi
- H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
- Form 6-K Telix Pharmaceuticals For: Jul 01
- Telix gets FDA alignment to expand prostate cancer trial to U.S.
- FDA Alignment to Advance ProstACT Global Phase 3 Trial
- Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Entities mentioned with TLX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- Earnings | View Related Stories »
- Show More...
